MapLight Therapeutics (MPLT) Preferred Stock Liabilities (2024 - 2025)
MapLight Therapeutics recorded quarterly Preferred Stock Liabilities of $225.0 million in Q3 2025, little changed quarter-over-quarter from $225.0 million in Q4 2024, and little changed year-over-year from $225.0 million in Q3 2024.
MapLight Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $225.0 million for Q3 2025.
- In Q3 2025, Preferred Stock Liabilities changed 0.0% year-over-year to $225.0 million; the TTM figure through Sep 2025 stood at $225.0 million (changed 0.0% YoY), while the FY2024 annual figure was $225.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $225.0 million for Q3 2025 at MapLight Therapeutics, roughly flat from $225.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $225.0 million in Q3 2024 to a low of $225.0 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 224.99 Mn |
| Dec 31, 2024 | 224.99 Mn |
| Sep 30, 2024 | 224.99 Mn |